Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Montaser

Showing results (611-620 of 613) with videos related to

Pageof 62
Sort By:
You have reached the last page of results.This site can display upto 613 results.
Journal for Immunotherapy of Cancer|October 2, 2021
Multicenter, double-blind, placebo-controlled trial of seviprotimut-L polyvalent melanoma vaccine in patients with post-resection melanoma at high risk of recurrenceCraig L Slingluff, Karl D Lewis, Robert Andtbacka, et al.
The Journal of Clinical Investigation|September 9, 2025
Recessive TMEM167A variants cause neonatal diabetes, microcephaly, and epilepsy syndromeEnrico Virgilio, Sylvia Tielens, Georgia Bonfield, et al.
The New England Journal of Medicine|March 1, 2023
Neoadjuvant-Adjuvant or Adjuvant-Only Pembrolizumab in Advanced MelanomaSapna P Patel, Megan Othus, Yuanbin Chen, et al.
Pageof 62

Showing results (611-620 of 613) with videos related to

Sort By:
Pageof 62
You have reached the last page of results.This site can display upto 613 results.
Journal for Immunotherapy of Cancer|October 2, 2021
Multicenter, double-blind, placebo-controlled trial of seviprotimut-L polyvalent melanoma vaccine in patients with post-resection melanoma at high risk of recurrenceCraig L Slingluff, Karl D Lewis, Robert Andtbacka, et al.
The Journal of Clinical Investigation|September 9, 2025
Recessive TMEM167A variants cause neonatal diabetes, microcephaly, and epilepsy syndromeEnrico Virgilio, Sylvia Tielens, Georgia Bonfield, et al.
The New England Journal of Medicine|March 1, 2023
Neoadjuvant-Adjuvant or Adjuvant-Only Pembrolizumab in Advanced MelanomaSapna P Patel, Megan Othus, Yuanbin Chen, et al.
Pageof 62